Predicting Chemo Toxicity Using Geriatric Forms

Correlation and Comparison Analyses of CARG, G8, and Frailty Tests in Predicting Chemotherapy-Associated Toxicity: A Prospective Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07163169

Enrollment

150

Registered

2025-09-09

Start date

2024-12-10

Completion date

2026-12-20

Last updated

2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geriatric Oncology, Oncology, Physiology

Keywords

geriatric oncology, chemotoxicity

Brief summary

This prospective observational study aims to evaluate and compare the effectiveness of three geriatric assessment tools-CARG (Cancer and Aging Research Group score), G8 screening tool, and Frailty Scale-in predicting chemotherapy-related toxicity (CRT) in cancer patients aged 65 years and older. A total of at least 100 patients receiving standard chemotherapy (excluding hematologic malignancies and immunotherapy) at Çanakkale University Medical Faculty Oncology Clinic will be assessed prior to treatment initiation. Each participant will undergo baseline evaluations including G8, CARG, and Frailty assessments. The study will analyze the correlation between these tools and the occurrence of CRT using AUC, logistic regression, and correlation analyses. The goal is to identify the most accurate and practical screening tool to guide clinical decision-making and minimize chemotherapy toxicity in older adults.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients aged 65 years or older. * Histologically confirmed cancer diagnosis with a pre-planned chemotherapy regimen (adjuvant, neoadjuvant, or palliative intent). * Chemotherapy not yet initiated at the time of enrollment. * Clinically stable condition, as assessed by the oncologist. * Willingness and ability to provide written informed consent.

Exclusion criteria

* Presence of acute infection or advanced organ failure (cardiac, hepatic, or renal). * Severe psychiatric illness or cognitive impairment that interferes with the ability to complete assessments. * Patients receiving concurrent hormonal therapy, targeted therapy, immunotherapy, or radiotherapy. * Diagnosis of hematologic malignancies (e.g., leukemia, lymphoma, myeloma).

Design outcomes

Primary

Measure	Time frame	Description
Geriartric Form Results and Chemotherapy Side Effects	From enrollment to 6 month	ARG (Cancer and Aging Research Group score)
G8 screening tool	From enrollment to 6 month	prediction side effets on chemotherapy on patient
Frailty Scale	From enrollment to 6 month	Predicting side effect chemoterapy in elderly patient

Countries

Turkey (Türkiye)

Outcome results